JXJia-Qi Xu

Jia-Qi Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jia-Qi Xu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • C. Y. Chen

    Jiaheng (Hengqin, Zhuhai) Pharmaceutical Technology Co., Ltd., Zhuhai, China

    1 shared publication
  • Hua Yu

    State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China

    1 shared publication
  • J. Gao

    National Engineering Research Center for Modernization of Traditional Chinese Medicine, Zhuhai, China

    1 shared publication
  • Jianli Guan

    Henan Fusen Pharmaceutical Co., Ltd., Henan, China

    1 shared publication
  • Jing-Yi Tang

    Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    1 shared publication
  • Lin-Xuan Xiao

    State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao 999078, China

    1 shared publication

Latest Publications

  • Open Access

    Mechanisms of Ganweikang Tablets against Chronic Hepatitis B: A Comprehensive Study of Network Analysis, Molecular Docking, and Chemical Profiling

    by Jia-Qi Xu, Shi-Bing Su, C. Y. Chen, J. Gao, Z. M. Cao, J. L. Guan, Lin-Xuan Xiao, Ming-Ming Zhao, Hua Yu, Yuan-Jia Hu

    The hepatitis B virus (HBV) is one of the major viral infection problems worldwide in public health. The exclusive proprietary Chinese medicine Ganweikang (GWK) tablet has been marketed for years in the treatment of chronic hepatitis B (CHB). However, the pharmacodynamic material basis and underlying mechanism of GWK are not completely clear. This study is aimed at investigating the pharmacological mechanism of the GWK tablet in the treatment of CHB. The chemical ingredient information was obtained from the Traditional Chinese Medicine Database and Analysis Platform (TCMSP), Traditional Chinese Medicines Integrated Database (TCMID), and Shanghai Institute of Organic Chemistry of CAS. Ingredients and disease‐related targets were defined by a combination of differentially expressed genes from CHB transcriptome data and open‐source databases. Target‐pathway‐target (TPT) network analysis, molecular docking, and chemical composition analysis were adopted to further verify the key targets and corresponding active ingredients of GWK. Eight herbs of GWK were correlated to 330 compounds with positive oral bioavailability, and 199 correlated targets were identified. The TPT network was constructed based on the 146 enriched targets by KEGG pathway analysis, significantly associated with 95 pathways. Twenty‐five nonvolatile components and 25 volatile components in GWK were identified in UPLC‐QTOF/MS and GC‐MS chromatograms. The key active ingredients of GWK include ferulic acid, oleanolic acid, ursolic acid, tormentic acid, 11‐deoxyglycyrrhetic acid, dibenzoyl methane, anisaldehyde, wogonin, protocatechuic acid, psoralen, caffeate, dimethylcaffeic acid, vanillin, β‐amyrenyl acetate, formonentin, aristololactam IIIa, and 7‐methoxy‐2‐methyl isoflavone, associated with targets CA2, NFKB1, RELA, AKT1, JUN, CA1, CA6, IKBKG, FOS, EP300, CREB1, STAT1, MMP9, CDK2, ABCB1, and ABCG2.